The current study proposes the successful use of a mass spectrometry-imaging technology that explores the composition of biomolecules and their spatial distribution directly on-tissue to differentially classify benign and malignant cases, as well as different histotypes. To identify new specific markers, we investigated with this technology a wide histological Tissue Microarray (TMA)-based thyroid lesion series. Results showed specific protein signatures for malignant and benign specimens and allowed to build clusters comprising several proteins with discriminant capabilities. Among them, FINC, ACTB1, LMNA, HSP7C and KAD1 were identified by LC-ESI-MS/MS and found up-expressed in malignant lesions. These findings represent the opening of further investigations for their translation into clinical practice, e.g. for setting up new immunohistochemical stainings, and for a better understanding of thyroid lesions
Galli, M., Pagni, F., De Sio, G., Smith, A., Chinello, C., Stella, M., et al. (2017). Proteomic profiles of thyroid tumors by Mass Spectrometry-Imaging on Tissue Microarrays. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 1865(7), 817-827 [10.1016/j.bbapap.2016.11.020].
Proteomic profiles of thyroid tumors by Mass Spectrometry-Imaging on Tissue Microarrays
GALLI, MANUELPrimo
;PAGNI, FABIOSecondo
;SMITH, ANDREW JAMES;CHINELLO, CLIZIA;STELLA, MARTINA;L'Imperio, V;MAURI, GIANCARLO;ZOPPIS, ITALO FRANCESCOPenultimo
;MAGNI, FULVIO
Ultimo
2017
Abstract
The current study proposes the successful use of a mass spectrometry-imaging technology that explores the composition of biomolecules and their spatial distribution directly on-tissue to differentially classify benign and malignant cases, as well as different histotypes. To identify new specific markers, we investigated with this technology a wide histological Tissue Microarray (TMA)-based thyroid lesion series. Results showed specific protein signatures for malignant and benign specimens and allowed to build clusters comprising several proteins with discriminant capabilities. Among them, FINC, ACTB1, LMNA, HSP7C and KAD1 were identified by LC-ESI-MS/MS and found up-expressed in malignant lesions. These findings represent the opening of further investigations for their translation into clinical practice, e.g. for setting up new immunohistochemical stainings, and for a better understanding of thyroid lesions
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
